reported that 10058-F4 exerts anticancer effects via the upregulation of the expression of FOXO transcription factors and their downstream genes, such as FasL, thereby inducing apoptosis in ovarian cancer cells (24). This evidence concerns the gene FASLG and ovarian carcinoma.